The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic

International Journal of Clinical Practice

Volumn 67, Issue 2, 2013, Pages 161-169

  Smith, M ^a   Blaker, P ^a   Patel, C ^b   Marinaki, A ^c   Arenas, M ^c   Escuredo, E ^c   Anderson, S ^a   Irving, P ^a   Sanderson, J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KINGSTON HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ALLOPURINOL; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; THIOGUANINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL DECISION MAKING; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG OVERDOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG UNDERDOSE; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SCHOOL CHILD; UNITED KINGDOM;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AZATHIOPRINE; BIOMARKERS, PHARMACOLOGICAL; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MEDICATION ADHERENCE; METHYLTRANSFERASES; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872308874     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12039     Document Type: Article

References (60)

1. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
2. Dubinsky MC,. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-43.
3. Pearson DC, May GR, Fick G, Sutherland LR,. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2009; (1): CD000067.
4. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C,. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2009; (4): CD000545.
5. Sokol H, Seksik P, Carrat F, et al., Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-8.
6. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP,. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41.
7. D'Haens G, Baert F, Van Assche G, et al., Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
8. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F,. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
9. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB,. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-6.
10. Yip JS, Woodward M, Abreu MT, Sparrow MP,. How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis 2008; 14: 514-8.
11. Ling YH, Chan JY, Beattie KL, Nelson JA,. Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol 1992; 42: 802-7.
12. Somerville L, Krynetski EY, Krynetskaia NF, et al., Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 2003; 278: 1005-11.
13. Swann PF, Waters TR, Moulton DC, et al., Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-11.
14. Tidd DM, Paterson AR,. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34: 738-46.
15. Tiede I, Fritz G, Strand S, et al., CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45.
16. Thomas CW, Myhre GM, Tschumper R, et al., Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 2005; 312: 537-45.
17. Ansari A, Hassan C, Duley J, et al., Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
18. Bloomfeld RS, Onken JE,. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003; 17: 69-73.
19. Kwan LY, Devlin SM, Mirocha JM, Papadakis KA,. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis 2008; 40: 425-32.
20. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM,. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2: 410-7.
21. Dubinsky MC, Yang H, Hassard PV, et al., 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
22. Ansari A, Elliott T, Baburajan B, et al., Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 734-41.
23. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB,. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14.
24. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD,. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012; 6: 905-12.
25. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD,. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
26. Cuffari C, Theoret Y, Latour S, Seidman G,. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
27. Wright S, Sanders DS, Lobo AJ, Lennard L,. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-8.
28. Hindorf U, Lyrenas E, Nilsson A, Schmiegelow K,. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1105-12.
29. Morales A, Salguti S, Miao CL, Lewis JD,. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 380-5.
30. Goldenberg BA, Rawsthorne P, Bernstein CN,. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 1744-8.
31. Gearry RB, Barclay ML, Roberts RL, et al., Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005; 35: 580-5.
32. Gearry RB, Barclay ML,. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-57.
33. Roblin X, Serre-Debeauvais F, Phelip JM, et al., 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005; 21: 829-39.
34. Armstrong L, Sharif JA, Galloway P, McGrogan P, Bishop J, Russell RK,. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine. Aliment Pharmacol Ther 2011; 34: 1106-14.
35. Belaiche J, Desager JP, Horsmans Y, Louis E,. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36: 71-6.
36. Decaux G, Prospert F, Horsmans Y, Desager JP,. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135: 256-62.
37. Glas J, Torok HP, Daczo J, Tonenchi L, Folwaczny M, Folwaczny C,. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur J Med Res 2005; 10: 535-8.
38. Colonna T, Korelitz BI,. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994; 89: 362-6.
39. Thomas CW Jr, Lowry PW, Franklin CL, et al., Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003; 9: 237-45.
40. Garza A, Sninsky C,. Change in red cell MCV during treatment with azathioprine or 6MP for Crohn's disease. Gastroenterology 2007; 120 (Supp. 1): A4
41. Jobson B, Garza A, Sninsky C,. Red cell MCV correlates with 6TGN levels during azathioprine or 6MP treatment for Crohn's disease. Gastroenterology 2001; 120 (Supp. 1): A4.
42. Achkar JP, Stevens T, Easley K, Brzezinski A, Seidner D, Lashner B,. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 339-45.
43. Lobel EZ, Korelitz BI, Vakher K, Panagopoulos G,. Prolonged remission of severe Crohn's disease after fever and leukopenia caused by 6-mercaptopurine. Dig Dis Sci 2004; 49: 336-8.
44. Persley KM, Present DH,. Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2001; 13: 1053-5.
45. Govani SM, Higgins PD,. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010; 4: 444-9.
46. Waljee AK, Joyce JC, Wang S, et al., Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin Gastroenterol Hepatol 2010; 8: 143-50.
47. Dewit O, Starkel P, Roblin X,. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest 2010; 40: 1037-47.
48. Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A, et al., Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011; 34: 544-54.
49. Carter MJ, Lobo AJ, Travis SP,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl. 5): V1-16.
50. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W,. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 935-9.
51. Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H,. Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; Epub 2010 Jan 13.
52. Dignass A, Van AG, Lindsay JO, et al., The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
53. Dervieux T, Boulieu R,. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998; 44: 551-5.
54. Gupta P, Gokhale R, Kirschner BS,. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 450-4.
55. Reinshagen M, Schutz DE, Armstrong VW, et al., 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn's disease: results from a randomized, controlled, open trial. Clin Chem 2007; 53: 1306-14.
56. von AN, Armstrong VW, Behrens C, et al., Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 2005; 51: 2282-8.
57. Haines ML, Ajlouni Y, Irving PM, et al., Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1301-7.
58. Ansari A, Arenas M, Greenfield SM, et al., Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 973-83.
59. Lennard L, Thomas S, Harrington CI, Maddocks JL,. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985; 113: 723-9.
60. Derijks LJ, Gilissen LP, Engels LG, et al., Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-8.